Omron Corp (OMRNY) Stock Analysis
Verdict: AVOID
Severe earnings misses and contracting margins collide with an overextended 41x P/E valuation, making the recent price surge unsustainable.
Investment score: 38/100
Analysis as of
Is Omron Corp stock worth reviewing? The TradeMates thesis
Omron Corp is currently priced for a perfection it is not delivering. Despite a strong brand in automation and healthcare, the company is struggling with significant earnings misses and deteriorating operating margins. The technical setup near 52-week highs is not supported by the underlying cash flow or valuation metrics.
7-factor investment score
- Valuation: 25/100 (weight 20%)
- Financial Health: 50/100 (weight 15%)
- Technical Momentum: 70/100 (weight 15%)
- Earnings Quality: 15/100 (weight 15%)
- Insider Sentiment: 50/100 (weight 10%)
- Analyst Consensus: 55/100 (weight 10%)
- Risk-Adjusted Return: 30/100 (weight 15%)
Omron Corp opportunities and risks
What speaks for OMRNY
- Industrial Automation Recovery
What speaks against OMRNY
- Execution Failure and Earnings Reliability
Peers and competitors
- 6981.T
- 6762.T
- 6971.T
- 4062.T
- 6976.T
Frequently asked questions about Omron Corp (OMRNY)
Is OMRNY stock a good investment?
The TradeMates model rates Omron Corp as AVOID with an investment score of 38/100. Omron Corp is currently priced for a perfection it is not delivering. Despite a strong brand in automation and healthcare, the company is struggling with significant earnings misses and deteriorating operating margins. The technical setup near 52-week highs is not supported by the underlying cash flow or valuation metrics. This is algorithmic model output, not personal investment advice.
Is OMRNY stock a buy?
The TradeMates model verdict for OMRNY is AVOID with an investment score of 38/100. Treat this as a model signal to review, not a personal buy recommendation.